Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation

For the Fukuoka Blood and Marrow Transplantation Group

研究成果: ジャーナルへの寄稿記事

抄録

Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE-MM and four TI-MM patients with hematological malignancies and ten TE-MM and eight TI-MM patients with non-hematological cancers, respectively. The median follow-up time from diagnosis was > 4 years. Multivariate analysis identified a history of high-dose cyclophosphamide use for peripheral blood stem cell harvest in TE-MM patients and > 65 years of age at diagnosis, or a history of adriamycin, lenalidomide, or thalidomide use in TI-MM patients as independent risk factors for SPMs (P < 0.001). Patients with a history of lenalidomide use had a lower risk of death among both TE-MM (P = 0.0326) and TI-MM (P < 0.001) patients. The survival benefit of receiving lenalidomide outweighed the increased risk of SPMs in both TE-and TI-MM patients.

元の言語英語
ページ(範囲)98-106
ページ数9
ジャーナルInternational journal of hematology
109
発行部数1
DOI
出版物ステータス出版済み - 1 22 2019

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Transplants
Neoplasms
Thalidomide
Hematologic Neoplasms
Life Expectancy
Doxorubicin
Cyclophosphamide

All Science Journal Classification (ASJC) codes

  • Hematology

これを引用

Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. / For the Fukuoka Blood and Marrow Transplantation Group.

:: International journal of hematology, 巻 109, 番号 1, 22.01.2019, p. 98-106.

研究成果: ジャーナルへの寄稿記事

For the Fukuoka Blood and Marrow Transplantation Group. / Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. :: International journal of hematology. 2019 ; 巻 109, 番号 1. pp. 98-106.
@article{9e3a5edcbf4f4d3e93c98599b3909552,
title = "Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation",
abstract = "Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE-MM and four TI-MM patients with hematological malignancies and ten TE-MM and eight TI-MM patients with non-hematological cancers, respectively. The median follow-up time from diagnosis was > 4 years. Multivariate analysis identified a history of high-dose cyclophosphamide use for peripheral blood stem cell harvest in TE-MM patients and > 65 years of age at diagnosis, or a history of adriamycin, lenalidomide, or thalidomide use in TI-MM patients as independent risk factors for SPMs (P < 0.001). Patients with a history of lenalidomide use had a lower risk of death among both TE-MM (P = 0.0326) and TI-MM (P < 0.001) patients. The survival benefit of receiving lenalidomide outweighed the increased risk of SPMs in both TE-and TI-MM patients.",
author = "{For the Fukuoka Blood and Marrow Transplantation Group} and Satoshi Yamasaki and Goichi Yoshimoto and Kentaro Kohno and Hideho Henzan and Takatoshi Aoki and Kazuki Tanimoto and Yasuhiro Sugio and Tsuyoshi Muta and Tomohiko Kamimura and Yuju Ohno and Ryosuke Ogawa and Tetsuya Eto and Koji Nagafuji and Toshihiro Miyamoto and Koichi Akashi and Hiromi Iwasaki",
year = "2019",
month = "1",
day = "22",
doi = "10.1007/s12185-018-2538-8",
language = "English",
volume = "109",
pages = "98--106",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation

AU - For the Fukuoka Blood and Marrow Transplantation Group

AU - Yamasaki, Satoshi

AU - Yoshimoto, Goichi

AU - Kohno, Kentaro

AU - Henzan, Hideho

AU - Aoki, Takatoshi

AU - Tanimoto, Kazuki

AU - Sugio, Yasuhiro

AU - Muta, Tsuyoshi

AU - Kamimura, Tomohiko

AU - Ohno, Yuju

AU - Ogawa, Ryosuke

AU - Eto, Tetsuya

AU - Nagafuji, Koji

AU - Miyamoto, Toshihiro

AU - Akashi, Koichi

AU - Iwasaki, Hiromi

PY - 2019/1/22

Y1 - 2019/1/22

N2 - Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE-MM and four TI-MM patients with hematological malignancies and ten TE-MM and eight TI-MM patients with non-hematological cancers, respectively. The median follow-up time from diagnosis was > 4 years. Multivariate analysis identified a history of high-dose cyclophosphamide use for peripheral blood stem cell harvest in TE-MM patients and > 65 years of age at diagnosis, or a history of adriamycin, lenalidomide, or thalidomide use in TI-MM patients as independent risk factors for SPMs (P < 0.001). Patients with a history of lenalidomide use had a lower risk of death among both TE-MM (P = 0.0326) and TI-MM (P < 0.001) patients. The survival benefit of receiving lenalidomide outweighed the increased risk of SPMs in both TE-and TI-MM patients.

AB - Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE-MM and four TI-MM patients with hematological malignancies and ten TE-MM and eight TI-MM patients with non-hematological cancers, respectively. The median follow-up time from diagnosis was > 4 years. Multivariate analysis identified a history of high-dose cyclophosphamide use for peripheral blood stem cell harvest in TE-MM patients and > 65 years of age at diagnosis, or a history of adriamycin, lenalidomide, or thalidomide use in TI-MM patients as independent risk factors for SPMs (P < 0.001). Patients with a history of lenalidomide use had a lower risk of death among both TE-MM (P = 0.0326) and TI-MM (P < 0.001) patients. The survival benefit of receiving lenalidomide outweighed the increased risk of SPMs in both TE-and TI-MM patients.

UR - http://www.scopus.com/inward/record.url?scp=85053799795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053799795&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-2538-8

DO - 10.1007/s12185-018-2538-8

M3 - Article

C2 - 30251131

AN - SCOPUS:85053799795

VL - 109

SP - 98

EP - 106

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -